Endologix Announces that Art Taylor Joins Board of Directors

IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, is pleased to announce that Art Taylor has been appointed to the Endologix Board of Directors.

Art Taylor has over 30 years of experience in operational and financial executive leadership within the medical device, pharmaceutical, and high-tech industries. Mr. Taylor’s expertise extends to both publicly held companies and private, venture capital-backed firms. His sector experience is diverse, encompassing spine, electrophysiology, ophthalmology, hearing healthcare, and neurology. Mr. Taylor served as a member of the Board of Directors for several medical device firms that were subsequently acquired and is currently a Board member for three early stage companies, and Providence Medical Technology, a commercial stage company.

“We are excited to welcome Art Taylor to the Endologix Board of Directors,” expressed Matt Thompson, MD, President, and CEO of Endologix. “Art’s wide-ranging experience in the healthcare sector adds a remarkable depth of knowledge to our board. His strategic acumen will be invaluable as we advance towards the full market release of our DETOUR System and equally crucial as we continue to grow our abdominal aortic aneurysm (AAA) business globally.”

About Endologix

Endologix LLC is a California-based, global medical device company dedicated to improving patients’ lives by providing innovative therapies for the interventional treatment of vascular disease. Endologix’s therapeutic portfolio includes a variety of products in various stages of development that are designed to treat diseases that currently have clinically relevant unmet needs. Endologix’s commercial products, including the AFX®2 Endovascular AAA System, ALTO® Abdominal Stent Graft System, and the DETOUR™ System, are designed to treat a range of vascular diseases, from abdominal aortic aneurysms to lower limb peripheral vascular disease. Endologix is wholly owned by Deerfield Management, an investment management firm committed to advancing healthcare through investment, information, and philanthropy. The company has offices and manufacturing sites in Irvine, Milpitas and Santa Rosa, California. To learn more about Endologix, please visit https://www.endologix.com/.

Contacts

Marian Sedra, 949-433-4935